Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 0904 • ACR Convergence 2023
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Soo Park¹, Gloria Lutzny-Geier², Natalia Giltiay¹, Jazmin Bravo¹, Simone Sandoval¹, Joseph Cheng¹, Catherine Dong¹, Nicole Khoshnoodi¹, Ames Register¹, Daniel Anaya¹, Michael Aigner³, Andreas Mackensen³, Georg Schett⁴, Charles Kaplan¹, Dominic Borie¹, James Chung¹ and Tom Van Blarcom⁵, ¹Kyverna Therapeutics, Emeryville, CA, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Kyverna Therapuetics, Emeryville, CA
Background/Purpose: A significant unmet need remains in the treatment of relapsed and/or refractory B cell-driven autoimmune diseases, including systemic lupus erythematosus (SLE),systemic sclerosis (SSc), and…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0011 • ACR Convergence 2024
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Brandon Kwong¹, Daniel Anaya¹, Soo Park², Sunetra Biswas², Jeevitha Jeevan², Jesus Banuelos², Madison Strobach², Nicole Khoshnoodi¹, Timothy Klasson¹, Santiago Foos-Russ¹, Jennifer Zeng¹, Candice Gibson³, Jazmin Bravo², Simone Sandoval¹, Shouvonik Sengupta¹, Shairaz Shah¹, Tom Van Blarcom² and Karen Walker², ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emeryville, ³Kyverna Therapeutics, Inc., Emerybille
Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…
Abstract Number: 2427 • ACR Convergence 2024
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus
Ioanna Minopoulou¹, Olaf Penack², Fredrik Albach¹, Artur Wilhelm³, Arnd Kleyer⁴, Dominic Borie⁵, Vincent Casteleyn¹, Robert Biesen¹, Philipp Enghard⁶, Thomas Dörner⁷, Norman Drzeniek⁸, Jan Zernicke¹, Tobias Alexander³, Kamran Movassaghi², Marie Luise Hütter-Krönke⁹, Eva Schrezenmeier⁶, Adrian Schreiber¹⁰, udo schneider¹, Lars Bullinger¹¹, Gerhard Krönke¹² and David Simon¹³, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/ Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Kyverna Therapeutics, Inc., Emeryville, CA, ⁶Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany/ Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany/Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Immunology, Berlin, Germany, Berlin, Germany, ⁹Department of Hematology, Oncology and Cancer Immunology, Charité University Medicine Berlin, Campus Steglitz, Berlin, Germany, Berlin, Germany, ¹⁰Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany, Berlin, Germany, ¹¹Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany/ Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, Berlin, Germany, ¹²Rheumatology, Charité, Berlin, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising therapeutic option for treatment-refractory patients with B cell-mediated diseases such as systemic…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].